Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06431516
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-22
Brief Title:
LMCA Treatment Outcome
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
Clinical Outcomes of Medical Treatment for Patients With Significant Unprotected Left Main Coronary Artery Disease
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Left main coronary artery LMCA is a major branch of coronary artery and supplies a large bulk of myocardium
Revascularization by either surgical coronary bypass grafting CABG or percutaneous coronary intervention PCI is recommended for significant unprotected LMCA disease with CABG being preferred if there is significant involvement in other coronary arteries12 CABG has been demonstrated to confer survival benefit over medical therapies patients with LMCA in earlier clinical trials345 However these trials were performed before the wide adoption of modern medical therapies such as antiplatelet and statin Antiplatelet agents for example was only used in 32 of all patients in the Coronary Artery Surgery Study3 Modern day medical treatment for stable coronary artery diseases have been shown to be non-inferior to revascularization in both the COURAGE and ISCHEMIA trials67 However patients with LMCA involvement were mostly excluded from both of these studies In Hong Kong the average waiting time for an elective CABG for stable patients with LMCA is around 18 months during which time the patients are treated with modern medical therapies including high-intensity statin and antiplatelet
Revascularization by either surgical coronary bypass grafting CABG or percutaneous coronary intervention PCI is recommended for significant unprotected LMCA disease with CABG being preferred if there is significant involvement in other coronary arteries12 CABG has been demonstrated to confer survival benefit over medical therapies patients with LMCA in earlier clinical trials345 However these trials were performed before the wide adoption of modern medical therapies such as antiplatelet and statin Antiplatelet agents for example was only used in 32 of all patients in the Coronary Artery Surgery Study3 Modern day medical treatment for stable coronary artery diseases have been shown to be non-inferior to revascularization in both the COURAGE and ISCHEMIA trials67 However patients with LMCA involvement were mostly excluded from both of these studies In Hong Kong the average waiting time for an elective CABG for stable patients with LMCA is around 18 months during which time the patients are treated with modern medical therapies including high-intensity statin and antiplatelet
Detailed Description:
Left main coronary artery LMCA is a major branch of coronary artery and supplies a large bulk of myocardium
Revascularization by either surgical coronary bypass grafting CABG or percutaneous coronary intervention PCI is recommended for significant unprotected LMCA disease with CABG being preferred if there is significant involvement in other coronary arteries12 CABG has been demonstrated to confer survival benefit over medical therapies patients with LMCA in earlier clinical trials345 However these trials were performed before the wide adoption of modern medical therapies such as antiplatelet and statin Antiplatelet agents for example was only used in 32 of all patients in the Coronary Artery Surgery Study3 Modern day medical treatment for stable coronary artery diseases have been shown to be non-inferior to revascularization in both the COURAGE and ISCHEMIA trials67 However patients with LMCA involvement were mostly excluded from both of these studies In Hong Kong the average waiting time for an elective CABG for stable patients with LMCA is around 18 months during which time the patients are treated with modern medical therapies including high-intensity statin and antiplatelet
Revascularization by either surgical coronary bypass grafting CABG or percutaneous coronary intervention PCI is recommended for significant unprotected LMCA disease with CABG being preferred if there is significant involvement in other coronary arteries12 CABG has been demonstrated to confer survival benefit over medical therapies patients with LMCA in earlier clinical trials345 However these trials were performed before the wide adoption of modern medical therapies such as antiplatelet and statin Antiplatelet agents for example was only used in 32 of all patients in the Coronary Artery Surgery Study3 Modern day medical treatment for stable coronary artery diseases have been shown to be non-inferior to revascularization in both the COURAGE and ISCHEMIA trials67 However patients with LMCA involvement were mostly excluded from both of these studies In Hong Kong the average waiting time for an elective CABG for stable patients with LMCA is around 18 months during which time the patients are treated with modern medical therapies including high-intensity statin and antiplatelet
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None